Lv6
2350 积分 2024-02-08 加入
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic Leukemia
16天前
已完结
Fixed-duration ibrutinib–venetoclax with MRD-guided ibrutinib–obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial
17天前
已完结
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
17天前
已完结
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
3个月前
已完结
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial
3个月前
已完结
Safety and efficacy of FLAG-Ida-based therapy combined with venetoclax for the treatment for newly diagnosed and relapsed/refractory patients with AML – A systematic review
3个月前
已完结
Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML
4个月前
已完结
SOHO State of the Art Updates and Next Questions Acute Myeloid Leukemia: Current Status and Next Questions
4个月前
已完结
How I use Maintenance Therapy in Acute Myeloid Leukemia
4个月前
已完结
How I Treat: Differentiation Therapy in Acute Myeloid Leukemia
4个月前
已完结
皖公网安备34019202002308
